Martin Ungerer
Research Subjects
Martin Ungerer has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Götz Münch
Corimmun GmbH, Martinsried, Germany
2 shared publicationsA. Bültmann
Trigen AG, Martinsried
1 shared publicationA. Gillitzer
Trigen AG, Martinsried, Germany
1 shared publicationAndreas Bültmann
Corimmun GmbH, (Procorde GmbH) Martinsried, Germany
1 shared publicationG. Münch
Trigen AG, Martinsried
1 shared publicationHans-Peter Holthoff
Corimmun GmbH, (Procorde GmbH) Martinsried, Germany
1 shared publication
Latest Publications
- Open Access
- 1 November 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (11) , 1230-1239
Administration of the Cyclic Peptide COR-1 in Humans (Phase I Study): Ex Vivo Measurements of Anti-β1-Adrenergic Receptor Antibody Neutralization and of Immune Parameters
Aims: A novel concept for the treatment of heart failure is the neutralization of antibodies against the β1-adrenergic receptor (anti-β1AR-ab). In a rat model of autoimmune cardiomyopathy, the cyclic peptide COR-1 (given i.v. once monthly) neutralized anti-β1AR-abs and prevented anti-β1AR-ab-induced myocardial damage, and completely reverted cardiac dysfunction over 3–6 months. Methods and results: A clinical phase I trial was designed as a single-blinded, placebo-controlled study. Fifty human volunteers received COR-1 or matching placebo as a single i.v. administration with ascending doses (10–240 mg). Primary endpoints were safety and tolerability, while the pharmacokinetic profile of COR-1 was assessed as a secondary endpoint. All five investigated dose groups were well tolerated; no drug-related side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete plasma clearance within 60 min after administration. Pharmacodynamic investigation showed dose-dependent efficacy with almost complete scavenging of pathological anti-β1AR-abs ex vivo at the two highest doses. No anti-COR-1 autoantibodies occurred. No other effects on the immune system (such as an increase of crucial cytokines) were observed up to 43 days after drug administration, nor upon incubation of anti-β1AR-ab-positive patient blood samples with COR-1 ex vivo. Conclusions: COR-1 was shown to be safe after i.v. administration in vivo; no relevant side effects occurred. Efficacy was estimated from ex vivo investigation of the potency to neutralize specific anti-β1-AR-abs. Trial registration: NCT 01043146, Eudra CT 2008-07745-31.
- 1 November 2012
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 14 (11) , 1230-1239
Open AccessAdministration of the Cyclic Peptide COR-1 in Humans (Phase I Study): Ex Vivo Measurements of Anti-β1-Adrenergic Receptor Antibody Neutralization and of Immune Parameters
Aims: A novel concept for the treatment of heart failure is the neutralization of antibodies against the β1-adrenergic receptor (anti-β1AR-ab). In a rat model of autoimmune cardiomyopathy, the cyclic peptide COR-1 (given i.v. once monthly) neutralized anti-β1AR-abs and prevented anti-β1AR-ab-induced myocardial damage, and completely reverted cardiac dysfunction over 3–6 months. Methods and results: A clinical phase I trial was designed as a single-blinded, placebo-controlled study. Fifty human volunteers received COR-1 or matching placebo as a single i.v. administration with ascending doses (10–240 mg). Primary endpoints were safety and tolerability, while the pharmacokinetic profile of COR-1 was assessed as a secondary endpoint. All five investigated dose groups were well tolerated; no drug-related side effects occurred. Pharmacokinetics revealed a favourable profile with an almost complete plasma clearance within 60 min after administration. Pharmacodynamic investigation showed dose-dependent efficacy with almost complete scavenging of pathological anti-β1AR-abs ex vivo at the two highest doses. No anti-COR-1 autoantibodies occurred. No other effects on the immune system (such as an increase of crucial cytokines) were observed up to 43 days after drug administration, nor upon incubation of anti-β1AR-ab-positive patient blood samples with COR-1 ex vivo. Conclusions: COR-1 was shown to be safe after i.v. administration in vivo; no relevant side effects occurred. Efficacy was estimated from ex vivo investigation of the potency to neutralize specific anti-β1-AR-abs. Trial registration: NCT 01043146, Eudra CT 2008-07745-31.
- Open Access
- 1 January 2012
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 7 (2) , e12
Overexpression of ABCG1 Protein Attenuates Arteriosclerosis and Endothelial Dysfunction in Atherosclerotic Rabbits
Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits
- 1 January 2012
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 7 (2) , e12
Open AccessOverexpression of ABCG1 Protein Attenuates Arteriosclerosis and Endothelial Dysfunction in Atherosclerotic Rabbits
Overexpression of ABCG1 protein attenuates arteriosclerosis and endothelial dysfunction in atherosclerotic rabbits
- 1 October 2008
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (10) , 1757-1763
Effect of dominant negative SNAP‐23 expression on platelet function
- 1 October 2008
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 6 (10) , 1757-1763
Effect of dominant negative SNAP‐23 expression on platelet function